The FMS gene encodes the functional cell surface receptor for colony-stimulating factor 1, the macrophageand monocyte-specific growth factor. Codons 969 and 301 have been identified as potentially involved in promoting the transforming activity of FMS. Mutations at codon 301 are believed to lead to neoplastic transformation by ligand independence and constitutive tyrosine kinase activity of the receptor. The tyrosine residue at codon 969 has been shown to be involved in a negative regulatory activity, which is disrupted by amino acid substitutions. This study reports on the frequency of point mutations at these codons, in vivo, in human myeloid maligances and in normal subjects. We studied 110 patients [67 with myelodysplasia (MDS) and 48 with acute myeloblastic leukemia (AML)], 5 patients being studied at the MDS and the later AML stage of the disease. There was a total incidence of 12.7% (14/110) with mutations in codon 969 and 1.8% (2/110) with mutations in codon 301. Two patients had mutations in the AML stage of the disease but not in the preceding MDS and one had a mutation in the MDS stage but not upon transformation of AML. This is consistent with the somatic origin of these mutations. FMS mutations were most prevalent (20%) in chronic myelomonocytic leukemia and AML type M4 (23%), both of which are characterized by monocytic differentiation. One of 51 normal subjects had a constitutional codon 969 mutation, which may represent a marker for predisposition to myeloid malian.
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The FMS gene encodes for the receptor of the macrophageand monocyte-specific growth factor, colony-stimulating factor 1 (CSF-1) (1-3). The protein product of the gene is a cell surface glycoprotein that is expressed on cells of the monocyte/macrophage lineages and possesses ligand-dependent tyrosine-specific kinase activity (3, 4) . Binding of CSF-1 to its receptor is required for survival, proliferation, and differentiation of these cells in vitro. The FMS gene is the cellular homologue of the v-fms gene of the Susan McDonough feline sarcoma virus (5, 6) . The v-fms gene product exhibits ligandindependent tyrosine kinase activity (7, 8) and will transform cells in vitro, whereas the normal human FMS gene will not (9, 10) . DNA sequence analysis (11) has shown that the FMS and v-fms genes differ by a number of point mutations and by the replacement of the 50 amino acids at the carboxy C terminus of the human gene with 11 unrelated amino acids in the v-fms gene. This C-terminal deletion removes a tyrosine residue at codon 969 that negatively regulates the response of the gene product to CSF-1 stimulation (9, 12) . In vitro studies have shown that substitution of the tyrosine residue at codon 969 to phenylalanine up-regulates the stimulation of the receptor to CSF-1 but is insufficient to confer transforming activity on the gene (9) . Alterations in addition to Tyr-969 must therefore be necessary to fully activate the FMS gene in vitro.
In the light of the sequence differences between the v-fis and FMS, studies of chimeric v-fms/FMS proteins have highlighted codon 301, in the extracellular domain, to be functionally important. The human, feline, and murine FMS genes all encode leucine at this position, whereas the viral gene encodes a serine residue (13) . Substitution of Ser-301 for Leu-301 in the human FMS gene rendered the gene transforming in an in vitro assay (10 (22, 23) . Fifty-one normal blood samples were also studied, these being obtained from healthy blood donors, patients in the ophthalmology department, and healthy volunteers (17 aged 20-39, 13 aged 40-60, 21 aged 61-80). Fully informed consent was obtained from all individuals and the investigation was approved by the South Glamorgan Joint Ethics Committee.
DNA Extraction. High molecular weight DNA was extracted from cells as described (24) .
Abbreviations: CSF-1, colony-stimulating factor 1; AML, acute myeloblastic leukemia; MDS, myelodysplasia; CMML, chronic myelomonocytic leukemia; SA, sideroblastic anemia; RA, refractory anemia; RAEB, RA with excess blasts; PCR, polymerase chain reaction.
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The publication costs of this article were defrayed in part by page charge payment. This article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. §1734 solely to indicate this fact. 5. (25) . Two of 400,000 A phage clones were plaque purified. Restriction enzyme analysis showed these clones to be identical. A 2.5-kb BamHI fragment shown by hybridization to a codon 301 wild-type oligonucleotide probe (Fig. 1) to contain sequences around codon 301 was subcloned into a plasmid, pUC18. A sequencing primer (5'-TGAGGTTCTGCTCA-GAGCTC-3') 3' to codon 301 was designed from the published cDNA sequence (11) and synthesized (Applied Biosystems). This was used to obtain intronic sequences 5' to Polymerase Chain Reaction (PCR). Methods of amplification and hybridization were as described (27, 28) with modifications. Primers flanking codons 301 and %9 (Fig. 1 ) of the FMS gene were used. The primers were designed from cDNA sequences (11) and from sequences obtained by ourselves. Each sample was subject to two rounds of amplification each of 50 cycles with Taq polymerase (Thermus aquaticus DNA polymerase; Perkin-Elmer), using material from the first round as a template for the second. The samples were applied to the membrane without a vacuum. The filters were denatured in 0.5 M NaOH/1.5 M NaCl and neutralized in 1.5 M NaCl/0.5 M Tris, pH 7.5/0.001 M Na2EDTA prior to baking at 80°C. Filters were hybridized to mutant-specific oligonucleotide probes (Fig. 1 (Kodak) film for 2 hr to 3 days. Potential mutants were rescreened on independent filters and reamplified to confirm the presence of mutations. Only those that stably hybridized to the mutant probes with significant signals were scored positive. Each mutant was therefore assayed for two independent PCR reactions. This was a stringent screen as, unlike RAS mutations where a biological transformation assay could be employed to confirm the presence of the mutations (28), there is no similar biological assay for FMS mutations.
Statistical Analysis. Fischer's exact test (29) was employed to determine if the differences found between the groups were significantly different from the normal incidence.
RESULTS
A total of 110 patients with MDS or AML was investigated for the presence of FMS mutations in their peripheral blood leukocytes (Tables 1 and 2 ). DNA from 16 of 110 (14.5%) patients was found to have mutations. Fourteen of 110 patients had mutations at codon 969. A cysteine substitution for the wild-type tyrosine was the most prevalent alteration. Two of 110 patients had mutations at codon 301. The FMS mutation in a single patient (9) was shown to be present in leukocytes from the MDS (9A) and AML M5 (9B) stages but not in buccal epithelium (data not shown). Patients 15 and 16 had mutations in the AML stage of disease but not in the preceding MDS (representative filter in Fig. 2) . Patient 3 possessed a mutation at the MDS stage of the disease, which was apparently lost upon leukemic transformation. These results indicate that FMS mutations can occur at early and late stages of disease and hence may not represent an initiating event in the generation of the abnormal clone. These results are consistent with the somatic origin of these mutations. No patients were found to possess a mutation at codons 301 and 969. However, three patients (1, 4 , and 7) showed evidence of two mutations at the same codon. CMML and AML M4 samples, both characterized by significant monocytic differentiation, had the highest rate of FMS (29)]. In 1 of 51 (2%) normal subjects analyzed, a Cys-969 mutation was found to be present in peripheral blood. Analysis of buccal epithelial cells from this person showed the presence of the same mutation (Fig. 3) . This finding suggests that the Cys-969 mutation is constitutional in this instance.
DISCUSSION
We have described the finding of point mutations at codons 301 (2/110) and 969 (14/110) of the FMS gene in vivo in myeloid disease and in 1 of 51 normal subjects. Our results indicate that a mutation at codon 969, rather than codon 301, is the more common lesion in these patients. We speculate that in the hemopoietic environment, in the presence of CSF-1, mutations at codon 969 that alter a negative regulatory site may up-regulate the response of the receptor to ligand binding and thus confer a growth advantage to the cell. In vitro studies imply that mutations at codon 301 may be of little advantage in an environment with normal or increased levels of CSF-1 (10) . In patients with reduced CSF-1 levels, however, a codon 301 mutation may confer a growth advantage on a clone of cells. Studies are necessary to examine the relationship between serum CSF-1 levels and mutational status of the FMS gene in these patients.
In the feline system, FMS mutations at codons 301 and 374 are required in addition to a C-terminal modification involving the loss of codon 969 for a fully transformed phenotype in Rat-2 cells (13) (28, 30) possibly indicating that myelodysplastic or leukemic clones already showing potential monocytic differentiation may be especially susceptible to the transforming properties of these oncogenes.
A constitutional mutation has been demonstrated in one hematologically normal individual. This mutant allele may have been inherited from one patient or may have arisen during embryonic development. In view of the high percentage of CMML (20%) and AML M4 (23%) patients with a mutation at codon 969 this may represent a lesion involved in predisposition to these particular malignancies. To our knowledge, a constitutional point mutation in a protooncogene at a regulatory domain has not been reported previously. Further studies are necessary to determine the functional significance of these mutations.
